CD4-positive and CD8-positive T-lymphocyte (CD4+/CD8+ T cells)

CD4-positive and CD8-positive T-lymphocytes are the primary cellular components of the adaptive immune system, maturing in the thymus to provide specialized defense against pathogens and tumors (StatPearls, NBK554420). CD4-positive T-lymphocytes, known as helper T cells, coordinate the immune response by recognizing antigens presented by MHC class II molecules and secreting cytokines that regulate other immune cells (NIH, NCI Dictionary). CD8-positive T-lymphocytes, or cytotoxic T cells, directly identify and eliminate virally infected or malignant cells through the recognition of antigens on MHC class I molecules (PubMed, PMID: 23395356). These cell populations are central to the pathology of various diseases, including HIV/AIDS, which is characterized by the depletion of CD4-positive cells, and many cancers where T-cell exhaustion prevents effective immune surveillance (Nature Reviews Immunology, 2013). Therapeutic strategies targeting these cells include immunosuppressive agents that inhibit T-cell activation for transplant or autoimmune conditions, and checkpoint inhibitors that reinvigorate exhausted T cells in oncology (PubChem, CID 5281515).

Other names

Helper T cellsCytotoxic T cellsT-lymphocytesT cellsCD4+ T cellsCD8+ T cells

Drugs modulate these cells by inhibiting calcineurin to prevent cytokine synthesis (e.g., Cyclosporine), blocking the CD3 receptor to deplete T cells (e.g., Muromonab-CD3), or inhibiting immune checkpoints like PD-1 and CTLA-4 to restore anti-tumor activity (StatPearls, NBK554420; PubMed, PMID: 23395356).